Sanofi cancer drug expands

Sanofi was among a few companies that slipped through new indications for their therapies before the end of 2021, again pushing forward its PD-1 inhibitor Libtayo.

A TGA update detailing new or extended uses registered in December reveals it took only 43 working days to provisionally approve Libtayo for treatment of adults with a type of skin cancer called metastatic basal cell carcinoma (BCC) while it granted full registration for patients with locally advanced disease.

These new indications include patients who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.